Cullinan Oncology LLC Market Cap ($894.21 Million)
Market Cap & Net Worth: Cullinan Oncology LLC (CGEM)
Cullinan Oncology LLC market cap. Cullinan Oncology LLC (NASDAQ:CGEM) has a market capitalization of $894.21 Million ($894.21 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9051 globally and #2576 in its home market, demonstrating a 3.90% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cullinan Oncology LLC's stock price $14.93 by its total outstanding shares 61458046 (61.46 Million). Also see Cullinan Oncology LLC (CGEM) cash conversion ratio for how efficiently the company converts equity into cash flow.
Cullinan Oncology LLC Market Cap History (2021–2026)
Cullinan Oncology LLC market cap history from 2021 to 2026. Data shows change from $948.30 Million to $917.57 Million (-11.25% CAGR). Check CGEM live share price for real-time trading data and today's change.
Index Memberships
Cullinan Oncology LLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.03% | #258 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #968 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.05% | #150 of 263 |
Weight: Cullinan Oncology LLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cullinan Oncology LLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cullinan Oncology LLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Cullinan Oncology LLC equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
50.06x
Cullinan Oncology LLC's market cap is 50.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $948.30 Million | $18.94 Million | -$65.04 Million | 50.06x | N/A |
Competitor Companies of CGEM by Market Capitalization
Companies near Cullinan Oncology LLC in the global market cap rankings as of November 3, 2026. Also see total assets of Cullinan Oncology LLC for a full breakdown of the balance sheet.
Key companies related to Cullinan Oncology LLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Cullinan Oncology LLC (2021–2026)
Market capitalization of Cullinan Oncology LLC from 2021 to today. Between 2021 and today, Cullinan Oncology LLC's market cap moved from $948.30 Million to $ 917.57 Million, with a yearly change of -11.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $917.57 Million | +44.25% |
| 2025 | $636.09 Million | -15.02% |
| 2024 | $748.56 Million | +19.53% |
| 2023 | $626.26 Million | -3.41% |
| 2022 | $648.38 Million | -31.63% |
| 2021 | $948.30 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Cullinan Oncology LLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $894.21 Million USD |
| MoneyControl | $894.21 Million USD |
| MarketWatch | $894.21 Million USD |
| marketcap.company | $894.21 Million USD |
| Reuters | $894.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049,… Read more